Revenue Update on GW Pharmaceuticals PLC- ADR(NASDAQ:GWPH)

GW Pharmaceuticals PLC- ADR(NASDAQ:GWPH) announced the earnings results for Fiscal Year 2016 and Q3. The results came in during Pre-market on Aug 9, 2016. Company reported revenue of $3.10M. Analysts estimated a revenue of $3.66M. Earnings per share were $-0.06. Analysts had estimated an EPS of $-1.21.

In a different note, Janney Capital said it Initiates Coverage on GW Pharmaceuticals PLC- ADR, according to a research note issued on Jun 27, 2016. The shares have been rated ‘Sell’ by the firm. Cantor Fitzgerald said it Initiates Coverage on GW Pharmaceuticals PLC- ADR, according to a research note issued on Jun 2, 2016. The shares have been rated ‘Buy’ by the firm.

GW Pharmaceuticals PLC- ADR (GWPH) shares turned negative on Wednesdays trading session with the shares closing down -0.18 points or -0.22% at a volume of 4,54,396. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $82.57. The peak price level was also seen at $82.57 while the days lowest was $80. Finally the shares closed at $81.38. The 52-week high of the shares is $120.94 while the 52-week low is $35.83. According to the latest information available, the market cap of the company is $1,771 M.

GW Pharmaceuticals plc is a United Kingdom-based biopharmaceutical company. The Company is engaged developing a portfolio of cannabinoid medicines including Sativex for the treatment of multiple sclerosis spasticity and cancer pain and Epidiolex for the treatment of childhood epilepsy. The Company also engaged in developing cannabinoids medicines containing controlled substances as well as plant-based prescription pharmaceutical products. The Company’s product Sativex is approved in 27 countries and is used as a treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS). The Sativex is also in Phase III clinical development for the treatment of cancer pain the indication for the United States market.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *